Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 7—July 2023
Dispatch

Pulmonary Nontuberculous Mycobacteria, Ontario, Canada, 2020

Author affiliations: University of Toronto, Toronto, Ontario, Canada (T.K. Marras, M. Richard-Greenblatt, S. Brode, F.B. Jamieson, J.V. Kus); University Health Network and Mount Sinai Hospital, Toronto (T.K. Marras, S. Brode); Public Health Ontario, Toronto (P. Nelson, A. Peci, M. Richard-Greenblatt, A. Sullivan, F.B. Jamieson, J.V. Kus); University of Oxford, Oxford, UK (M. Richard-Greenblatt); West Park Healthcare Centre, Toronto (S. Brode)

Cite This Article

Abstract

We measured annual prevalence of microbiologically defined nontuberculous mycobacterial lung disease in Ontario, Canada. Mycobacterium avium prevalence was 13 cases/100,000 persons in 2020, a 2.5-fold increase from 2010, indicating a large increase in true M. avium lung disease. During the same period, M. xenopi decreased nearly 50%, to 0.84 cases/100,000 persons.

Nontuberculous mycobacterial (NTM) pulmonary disease (NTM-PD) is increasingly common and difficult to manage (1). Thus, understanding its epidemiology is essential but challenging because the diagnosis requires microbiological, radiological, and clinical information (1). Because NTM-PD is not reportable in most jurisdictions, data required to study its epidemiology are generally unavailable. Many investigators have thus solely used microbiological criteria as a surrogate disease definition (2). We previously observed large increases in Mycobacterium avium complex (MAC) isolation in Ontario, Canada, during 1998–2010 (3). We report more recent prevalence of NTM-PD in Ontario.

The Study

This retrospective cross-sectional study of persons in Ontario who had pulmonary NTM isolates during 2020 used Public Health Ontario’s laboratory records, which capture ≈95% of NTM in Ontario. We prepared cultures by using BACTEC MGIT 960 (Becton Dickinson, https://www.bd.com) and Lowenstein-Jensen slants. We used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, line-probe assays (GenoType; Hain Lifescience, https://www.hain-lifescience.de), a laboratory-developed MAC real-time PCR, or 16S rDNA sequencing to identify NTM to species/subspecies levels.

Figure 1

Categories of nontuberculous mycobacteria pulmonary disease, Ontario, Canada, 2020. A) Uncertain state: 1 sputum culture. B) Standard microbiological criteria: >2 sputum cultures with the same species, or 1 bronchoscopic or lung biopsy culture. C) Strict microbiological criteria (subset of standard): >3 sputum cultures with the same species, or >2 bronchoscopic cultures with the same species, or 1 bronchoscopic plus 1 sputum culture with the same species, or 1 lung biopsy culture. Some images were obtained from Flaticon (https://www.flaticon.com).

Figure 1. Categories of nontuberculous mycobacteria pulmonary disease, Ontario, Canada, 2020. A) Uncertain state: 1 sputum culture. B) Standard microbiological criteria: >2 sputum cultures with the same species, or 1...

Lacking clinical information, we defined surrogate NTM-PD criteria microbiologically, in 3 categories: uncertain (single sputum), standard (guidelines’ microbiological definition [1]), and strict (additional culture required) (Figure 1). Although standard microbiological criteria demonstrated a 70%–100% positive predictive value (3), we created the strict category (subset of standard) because it is unknown whether the diagnostic test characteristics might vary by potentially changing levels of environmental NTM exposure, possibly affecting frequencies of specimen contamination or colonization. Patients who had NTM isolated in 2020 had previous 24-month sample histories reviewed to determine if they reached disease thresholds. W used Statistics Canada population data for calculating prevalence and age- and sex-standardization (https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid = 1710000501). We performed analysis by using SAS Enterprise Guide 9.4 (SAS Institute, https://www.sas.com). The Public Health Ontario Ethics Review Board approved this study.

During 2020, the population of Ontario was 14,726,022, and of 41,471 pulmonary samples tested for mycobacteriology, 8,412 (20.3%) grew NTM. All-species prevalence (cases/100,000 population) by NTM-PD definition was as follows: uncertain, 12.9 (n = 1,899); standard, 19.2 (n = 2,824); and strict, 10.9 (n = 1,602), (Table 1, by species). Overall cases of standard (69.2%) and strict (73.1%) microbiological disease were caused mostly by M. avium (69.2% and 73.1%), followed by M. intracellulare (6.4% and 6.3%), M .abscessus (5.8% and 7.1%), and M. xenopi (4.4% and 3.9%).

More female than male patients were classified with standard disease (1,507 [53.4%] vs. 1,285 [45.5%]) and strict disease (892 [55.7%] vs. 696 [43.4%]) (Table 2). Substantial discrepancies in sex ratio from parity were seen for M. avium, M. intracellulare, and M. abscessus, favoring female patients, and M. gordonae, favoring male patients. Adjusting for population sex distribution did not greatly alter those observations.

Depending on species, patients who were ≥60 years of age comprised 63%–85% (74.2% overall) of those with standard disease and 61%–85% (76.9% overall) of those with strict disease (Appendix Table 1). Younger patients generally represented small minorities. Age-standardized prevalence ratio for all species combined increased from 0.05 in the youngest age group to 4.46 in the oldest age group among patients meeting standard criteria and from 0.07 to 4.56 among patients meeting strict criteria.

Figure 2

Prevalence of nontuberculous mycobacterial pulmonary disease (standard definition) by Ontario health region, Ontario, Canada, 2020. Numbers below region names indicate number of cases per 100,000 population.

Figure 2. Prevalence of nontuberculous mycobacterial pulmonary disease (standard definition) by Ontario health region, Ontario, Canada, 2020. Numbers below region names indicate number of cases per 100,000 population.

We found striking regional heterogeneity in the frequency of NTM-PD (Figure 2; Appendix Table 2). Prevalence of all-species NTM-PD, by standard and strict definitions was lowest in the North West region (3.8 vs. 2.9 cases/100,000 persons) and highest in Toronto (49.8 vs. 28.8 cases/100,000 persons). We compiled selected comparisons between nonoverlapping groups (exclusively standard versus strict definition patients) (Appendix Tables 3, 4).

Conclusions

In this population-based study of NTM-PD in Ontario, we observed high levels by using standard (19.0 cases/100,000 persons) and strict (10.9 cases/100,000 persons) microbiological criteria. M. avium comprised most of cases, followed distantly by M. intracellulare and M. abscessus and less commonly M. xenopi. The total NTM-PD prevalence (standard definition) of 19.0 cases/100,000 persons was nearly double the previously reported 9.8 cases/100,000 persons in 2010 (3). During the same period, M. xenopi prevalence decreased by nearly half, from 1.54 to 0.84 cases/100,000 persons, and M. abscessus increased 3.7-fold, from 0.30 to 1.11 cases/100,000 persons (3). In our previous study, M. avium was not separated from other MAC species, but ≈85% of contemporary Ontario MAC isolates were M. avium (4). The prevalence of M. avium pulmonary disease in Ontario, by standard microbiological definition, increased 2.5-fold, from 5.34 cases/100,000 persons in 2010 (3) to 13.27 cases/100,000 persons in 2020, explaining virtually all of the NTM-PD increase.

Historically, most population-based studies (2) and a recent large managed care study in the United States (5) have shown increases in NTM-PD. Trends in NTM species frequencies were reviewed in 8 recent population-based studies that had species-level data (613). In Denmark (1997–2008) (6) and Madrid, Spain (2013–2017) (7), there were no convincing trends. In Croatia (2006–2010), M. fortuitum increased (8). The remaining 5 studies demonstrated large increases in MAC (Barcelona/Catalonia in 1994–2014 [9]; Queensland, Australia, in 1999–2005 [10]; and the United Kingdom in 2007–2012 [11]) or specifically M. avium (the Netherlands in 2000–2006 [12] and Belgium in 2007–2016 [13]), without major changes in other species. The Ontario experience is similar, with the exception of the reduction in M. xenopi. Most other regions had increases in other species in addition to M. avium or MAC. The marked reduction in M. xenopi in this study is unexplained but might be related to the increase in M. avium. M. avium might be outcompeting M. xenopi in a common environmental niche or overgrowing the slow-growing M. xenopi in culture.

The main limitation of our study is the lack of clinical and radiological information. Defining NTM-PD solely on microbiological criteria over-estimates prevalence by misclassifying persons who fulfil microbiological criteria but not clinical/radiological criteria. Although microbiological criteria have good positive predictive values, the diagnostic test characteristics might be unstable (e.g., if there is a major change in NTM exposure). As suggested by hospital NTM pseudo-outbreaks (14), increased environmental NTM exposure might increase colonization or contamination of oropharyngeal and airway mucosal secretions and thereby specimens submitted for mycobacterial testing, thus reducing the positive predictive value of microbiological criteria for NTM-PD.

Given our uncertainties, we chose standard and strict for disease definitions, rather than previously used terms such as definite. Regardless, we believe that an increase in environmental NTM exposure, probably contributing to our large increase in M. avium isolation, would eventually cause increased disease. There were no changes in laboratory methods explaining the observed M. avium increase, and there was no consistent increase in contemporary specimen submission (increased testing bias). Given the absence of laboratory changes, we believe that the increase is related to increased environmental exposures, resulting in increased colonization and disease, or better patient identification for testing by clinicians. Concerning better patient identification for testing, the proportion of culture-positive pulmonary specimens increased from ≈10% in 2010 to 20.3% in 2020 (18.0% in 2018 and 19.3% in 2019). There was a near-linear increase in chest computed tomography (CT) scanning in Ontario during 2007–2016 (15), possibly increasing detection because CT scans identify characteristic findings of NTM, accurately driving clinical suspicion. Increased CT use probably contributes to greater detection of true disease, although it could not explain the reduction in M. xenopi.

In summary, this study identified a large increase in the prevalence of microbiologically defined M. avium lung disease in this region, undoubtedly indicating a large increase in the prevalence of true lung disease caused by M. avium. Clinicians should be aware of the causes of this increase and investigators should determine to what extent the increase in microbiologically defined disease reflects true disease.

Dr. Marras is an attending staff physician in the Division of Respirology, Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, and associate professor of medicine, University of Toronto and Director of the Toronto Western Hospital Nontuberculous Mycobacterial Program. His primary research interest is nontuberculous mycobacterial disease, with a particular interest in epidemiology.

Top

References

  1. Daley  CL, Iaccarino  JM Jr, Lange  C, Cambau  E, Wallace  RJ Jr, Andrejak  C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535. DOIPubMedGoogle Scholar
  2. Prevots  DR, Marras  TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36:1334. DOIPubMedGoogle Scholar
  3. Marras  TK, Mendelson  D, Marchand-Austin  A, May  K, Jamieson  FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013;19:188991. DOIPubMedGoogle Scholar
  4. Heffer  MJ, Al-Ghimlas  F, Hoffstein  V, Jamieson  FB, Mehta  M, Chedore  P, et al. Mycobacterium avium and Mycobacterium intracellulare: distinct pathogens or just a “complex”? In: Abstracts of the American Thoracic Society 2010 International Conference: New Orleans, Louisiana, May 14‒19, 2010. Am J Respir Crit Care Med. 2010;181:A2608.
  5. Winthrop  KL, Marras  TK, Adjemian  J, Zhang  H, Wang  P, Zhang  Q. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008‒2015. Ann Am Thorac Soc. 2020;17:17885. DOIPubMedGoogle Scholar
  6. Andréjak  C, Thomsen  VO, Johansen  IS, Riis  A, Benfield  TL, Duhaut  P, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181:51421. DOIPubMedGoogle Scholar
  7. López-Roa  P, Aznar  E, Cacho  J, Cogollos-Agruña  R, Domingo  D, García-Arata  MI, et al. Epidemiology of Non-Tuberculous Mycobacteria isolated from clinical specimens in Madrid, Spain, from 2013 to 2017. Eur J Clin Microbiol Infect Dis. 2020;39:108994. DOIPubMedGoogle Scholar
  8. Jankovic  M, Samarzija  M, Sabol  I, Jakopovic  M, Katalinic Jankovic  V, Zmak  L, et al. Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. Int J Tuberc Lung Dis. 2013;17:83641. DOIPubMedGoogle Scholar
  9. Santin  M, Barrabeig  I, Malchair  P, Gonzalez-Luquero  L, Benitez  MA, Sabria  J, et al. Pulmonary infections with nontuberculous mycobacteria, Catalonia, Spain, 1994‒2014. Emerg Infect Dis. 2018;24:10914. DOIPubMedGoogle Scholar
  10. Thomson  RM; NTM working group at Queensland TB Control Centre and Queensland Mycobacterial Reference Laboratory. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16:157683. DOIPubMedGoogle Scholar
  11. Shah  NM, Davidson  JA, Anderson  LF, Lalor  MK, Kim  J, Thomas  HL, et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect Dis. 2016;16:195. DOIPubMedGoogle Scholar
  12. van Ingen  J, Hoefsloot  W, Dekhuijzen  PN, Boeree  MJ, van Soolingen  D. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis. 2010;14:117680.PubMedGoogle Scholar
  13. Soetaert  K, Subissi  L, Ceyssens  P-J, Vanfleteren  B, Chantrenne  M, Asikainen  T, et al. Strong increase of true and false positive mycobacterial cultures sent to the National Reference Centre in Belgium, 2007 to 2016. Euro Surveill. 2019;24:1800205. DOIPubMedGoogle Scholar
  14. D’Antonio  S, Rogliani  P, Paone  G, Altieri  A, Alma  MG, Cazzola  M, et al. An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. Int J Mycobacteriol. 2016;5:2447. DOIPubMedGoogle Scholar
  15. Smith-Bindman  R, Kwan  ML, Marlow  EC, Theis  MK, Bolch  W, Cheng  SY, et al. Trends in use of medical imaging in US health care systems and in Ontario, Canada, 2000‒2016. JAMA. 2019;322:84356. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Cite This Article

DOI: 10.3201/eid2907.230216

Original Publication Date: May 30, 2023

Table of Contents – Volume 29, Number 7—July 2023

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Theodore K. Marras, Toronto Western Hospital, 7E-452, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada

Send To

10000 character(s) remaining.

Top

Page created: April 20, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external